User menu

Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.

Bibliographic reference Elens, Laure ; Yombi, Jean-Cyr ; Lison, Dominique ; Wallemacq, Pierre ; Vandercam, Bernard ; et. al. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.. In: Pharmacogenomics, Vol. 10, no.10, p. 1589-1597 (2009)
Permanent URL
  1. Kimchi-Sarfaty C., Oh J. M., Kim I.-W., Sauna Z. E., Calcagno A. M., Ambudkar S. V., Gottesman M. M., A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity, 10.1126/science.1135308
  2. Wang Danxin, Johnson Andrew D., Papp Audrey C., Kroetz Deanna L., Sadée Wolfgang, Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability : , 10.1097/01.fpc.0000178311.02878.83
  3. Woodahl Erica L, Yang Ziping, Bui Tot, Shen Danny D, Ho Rodney JY, MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells : , 10.1097/01.aids.0000183626.74299.77
  4. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H., Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase., 10.1073/pnas.83.21.8333
  5. Elens L., Veriter S., Yombi J.C., Di Fazio V., Vanbinst R., Lison D., Wallemacq P., Vandercam B., Haufroid V., Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells, 10.1016/j.jchromb.2009.04.046
  6. Elens L., Veriter S., Di Fazio V., Vanbinst R., Boesmans D., Wallemacq P., Haufroid V., Quantification of 8 HIV-Protease Inhibitors and 2 Nonnucleoside Reverse Transcriptase Inhibitors by Ultra-Performance Liquid Chromatography with Diode Array Detection, 10.1373/clinchem.2008.108647
  7. Oselin Kersti, Mrozikiewicz Przemyslaw M., Pahkla Rein, Roots Ivar, Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+cells, 10.1034/j.1600-0609.2003.00100.x
  8. Nies Anne T., Keppler Dietrich, The apical conjugate efflux pump ABCC2 (MRP2), 10.1007/s00424-006-0109-y
  9. Mahungu T W, Johnson M A, Owen A, Back D J, The impact of pharmacogenetics on HIV therapy, 10.1258/ijsa.2008.008369
  10. Telenti A., Zanger U. M., Pharmacogenetics of Anti-HIV Drugs, 10.1146/annurev.pharmtox.48.113006.094753
  11. Winzer, Eur. J. Med. Res., 8, 531 (2003)
  12. Ma Qing, Brazeau Daniel, Zingman Barry S, Reichman Richard C, Fischl Margaret A, Gripshover Barbara M, Venuto Charles S, Slish Judianne C, DiFrancesco Robin, Forrest Alan, Morse Gene D, Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV, 10.2217/14622416.8.3.227
  13. Estrela RCE, Santoro AB, Barroso PF, Tuyama M, Suarez-Kurtz G, CYP3A5 Genotype Has No Impact on Plasma Trough Concentrations of Lopinavir and Ritonavir in HIV-infected Subjects, 10.1038/clpt.2008.12
  14. Kuehl Peter, Zhang Jiong, Lin Yvonne, Lamba Jatinder, Assem Mahfoud, Schuetz John, Watkins Paul B., Daly Ann, Wrighton Steven A., Hall Stephen D., Maurel Patrick, Relling Mary, Brimer Cynthia, Yasuda Kazuto, Venkataramanan Raman, Strom Stephen, Thummel Kenneth, Boguski Mark S., Schuetz Erin, 10.1038/86882
  15. Kliewer, J. Nutr., 133, S2444 (2003)
  16. Agarwal Sheetal, Pal Dhananjay, Mitra Ashim K., Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor, 10.1016/j.ijpharm.2007.02.036
  17. Kumar, Drug Metab. Dispos., 27, 902 (1999)
  18. Breilh Dominique, Pellegrin Isabelle, Rouzés Agnés, Berthoin Karine, Xuereb Fabien, Budzinski Hélène, Munck Michèle, Fleury Hervé JA, Saux Marie-Claude, Pellegrin Jean-Luc, Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study) : , 10.1097/00002030-200406180-00009
  19. Wateba MI, Billaud E, Dailly E, Jolliet P, Raffi F, Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients, 10.1111/j.1468-1293.2006.00354.x
  20. Aarnoutse Rob E, Schapiro Jonathan M, Boucher Charles A B, Hekster Yechiel A, Burger David M, Therapeutic Drug Monitoring : An Aid to Optimising Response to Antiretroviral Drugs?, 10.2165/00003495-200363080-00002
  21. Voigt E., Wasmuth J.-C., Vogel M., Mauss S., Schmutz G., Kaiser R., Rockstroh J.-K., Safety, Efficacy and Development of Resistance under the New Protease Inhibitor Lopinavir/Ritonavir: 48-Week Results, 10.1007/s15010-004-3059-3
  22. TsengA, Loufty M, Philips E, Walker S, Rachlis A, Walmsley S: The relationship between lipid elevation and lopinavir (LPV) concentrations in HIV-infected patients on LPV/r-containing salvage regiment. Presented at:Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA, 27–30 September 2002 Abstract H1916).
  23. Gutiérrez Félix, Padilla Sergio, Navarro Andrés, Masiá Mar, Hernández Ildefonso, Ramos José, Esteban Angel, Martin-Hidalgo Alberto, Lopinavir Plasma Concentrations and Changes in Lipid Levels During Salvage Therapy with Lopinavir/Ritonavir-Containing Regimens : , 10.1097/00126334-200308150-00007
  24. González de Requena Daniel, Blanco Francisco, Garcia-Benayas Teresa, Jiménez-Nácher Inmaculada, González-Lahoz Juan, Soriano Vincent, Correlation Between Lopinavir Plasma Levels and Lipid Abnormalities in Patients Taking Lopinavir/Ritonavir, 10.1089/108729103322395465
  25. Kaplan S. S., Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection, 10.1093/jac/dki209